




APIs Pipeline

Venetoclax



Venetoclax (CAS-RN 1257044-40-8) is an antineoplastic agent approved in 2016 by US FDA to treat patients with Chronic Lymphocytic Leukemia (CLL).

Venetoclax is a potent and selective inhibitor of the antiapoptotic protein BCL-2 (B-cell lymphoma). It binds directly to the binding site of the BH3 domain of BCL-2 and thereby displaces proapoptotic proteins with BH3 domains, such as BIM, to initiate permeabilization of the mitochondrial outer membrane (MOMP), caspase activation and programmed cell death.

Main Therapeutic Application

ANTINEOPLASTIC

CAS-RN

1257044 - 40 -8

Specification

In House

Documentation

Under Development

Lebsa

+34 93 377 00 51
lebsa@lebsa.com
www.lebsa.com

MADE IN EUROPE

HEADQUARTERS:
Ctra. de l'Hospitalet, 34
08940 Cornellà (Barcelona)
SPAIN

**Are you looking for
other molecules?**


For more information about our R&D
pipeline and CDMO services

CONTACT US



APIs Pipeline

Octenidine dihydrochloride



Octenidine dihydrochloride is a cationic antiseptic belonging to the bispyridine class of chemicals and being effective against gram-positive and gram-negative bacteria. It is an antiseptic agent intended for use in oral hygiene, preventing plaque and gingivitis, as a whole body wash for methicillin-resistant *S. aureus* (MRSA) decolonization, for skin disinfection of premature newborn infant, and short-term supportive antiseptic wound treatment as a 0.1% aqueous solution for cutaneous use.

Main Therapeutic Application

ANTISEPTIC

CAS-RN

70775-75-6

Specification

In House

Documentation

Under Development

Lebsa

+34 93 377 00 51
lebsa@lebsa.com
www.lebsa.com

HEADQUARTERS:
Ctra. de l'Hospitalet, 34
08940 Cornellà (Barcelona)
SPAIN

MADE IN EUROPE

**Are you looking for
other molecules?**


For more information about our R&D
pipeline and CDMO services

CONTACT US



APIs Pipeline

Letermovir



Letermovir (CAS-RN 917389-32-3) is an antiviral agent approved in 2017 by US FDA to be used in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Designated an orphan drug by FDA for prevention of CMV viremia and disease in at-risk populations.

Main Therapeutic Application

ANTIVIRAL

CAS-RN

917389-32-3

Specification

In House

Documentation

Under Development

Lebsa

+34 93 377 00 51
lebsa@lebsa.com
www.lebsa.com

MADE IN EUROPE

HEADQUARTERS:
Ctra. de l'Hospitalet, 34
08940 Cornellà (Barcelona)
SPAIN

**Are you looking for
other molecules?**

For more information about our R&D
pipeline and CDMO services

CONTACT US